Lonza Aktie

Kaufen

Verkaufen

Handeln Handeln

603,80 EUR -1,00 EUR -0,17 %

08:12:46

FSE

567,37 CHF +9,61 CHF +1,72 %

27.05.2025

BRX

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.42,58 Mrd. EUR

KGV59,96Div. Rendite0,75%

WKN928619

ISINCH0013841017

SymbolLZAGF

Lonza Aktien News

Sortieren:Datum Meistgelesen

26.01.24EQS GroupLonza Delivers Solid 2023 Performance with 10.9% CER Sales Growth and 29.8% CORE EBITDA Margin

06.11.23EQS GroupLonza Prices CHF 400 Million Dual-Tranche Straight Bonds

17.10.23EQS GroupCapital Markets Day 2023: New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects

13.10.23EQS GroupLonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer

21.09.23EQS GroupLonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023

18.09.23EQS GroupBoard Announcement

13.09.23PR NewswireABL Bio Taps into Synaffix ADC Technology to Accelerate Development of Bispecific ADC Products

21.07.23EQS GroupLonza Delivers 5.6% CER Sales Growth, With Underlying Growth at Around 10% CER and 30% CORE EBITDA Margin

01.06.23EQS GroupLonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering

10.05.23EQS GroupQ1 2023 Qualitative Update: Business Performance In Line With Full-Year Trajectory

05.05.23EQS GroupLonza Announces Results of the 2023 Annual General Meeting All Motions Proposed by Board of Directors Accepted

20.04.23EQS GroupLonza Increases Straight Bond by CHF 150 Million

31.03.23EQS GroupLonza Launches Share Buyback Program of up to CHF 2 Billion

29.03.23EQS GroupLonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)

27.03.23EQS GroupLonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports

16.02.23EQS GroupLonza Completes Expansion of Conjugation Facility in Visp (CH)

08.02.23EQS GroupLonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon

25.01.23EQS GroupLonza Delivers Strong 2022 Performance with 15.1% CER Sales Growth and 32.1% CORE EBITDA Margin

01.11.22EQS GroupLonza Launches New Capsule to Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine

12.09.22EQS GroupLonza Appoints Daniel Palmacci as President of the Cell & Gene Division

06.09.22EQS GroupLonza and Touchlight collaborate on end-to-end mRNA offering

22.07.22EQS GroupLonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin

01.07.22EQS GroupMaria Soler Nunez appointed as Head, Group Operations

01.07.22EQS GroupLonza to Establish Large-Scale, Commercial Drug Product Fill & Finish Facility in Stein (CH)

05.06.20ReutersLonza picks Roche exec as CEO, ending year of turmoil at the top

05.06.20ReutersLonza names Roche executive as CEO, underscoring pharmaceuticals focus

02.06.20ReutersExclusive: Lonza sets new goal to make Moderna COVID-19 vaccine ingredients

20.05.20ReutersUPDATE 1-Lonza CEO says up to Moderna who would get COVID-19 vaccine first - CNBC

20.05.20ReutersLonza CEO says on pace to make Moderna trial vaccine in June/July - CNBC

01.05.20ReutersModerna, Switzerland's Lonza strike deal on potential COVID-19 vaccine

17.02.20ReutersLonza poised to mandate banks for specialty chemicals spinoff - sources

03.09.19ReutersUPDATE 1-Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals

Lonza News

Lonza News: auf dieser Seite finden Sie alle Lonza News und Nachrichten zur Lonza Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Lonza News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Lonza News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.